<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531568</url>
  </required_header>
  <id_info>
    <org_study_id>MT-3995-E10</org_study_id>
    <nct_id>NCT02531568</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of Warfarin and MT-3995</brief_title>
  <official_title>A Phase I, Open-label, Single-Centre, Drug-Drug Interaction Study to Evaluate the Influence of MT-3995 on Pharmacokinetics(PK) and Pharmacodynamics of Warfarin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of MT-3995 on the PK of warfarin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the potential effects of multiple once daily doses
      of MT-3995 on the PK of (S)-warfarin and (R)-warfarin after single-dose administration of
      racemic warfarin
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of warfarin with MT-3995 versus warfarin alone</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of warfarin with MT-3995 versus warfarin alone</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>International normalized ratio (INR) max of warfarin with MT-3995 versus warfarin alone</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR AUC of warfarin with MT-3995 versus warfarin alone</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Warfarin and MT-3995</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered a single dose of warfarin on day1. Subjects will be administered MT-3995 Days 8 to 20. Subjects will be administered MT-3995 and warfarin on Day21. Subjects will be administered MT-3995 from Day 22 to 27.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>Warfarin and MT-3995</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-3995</intervention_name>
    <arm_group_label>Warfarin and MT-3995</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to provide written informed consent to participate in this study

          -  Healthy, free from clinically significant illness or disease

          -  White Caucasian male or female, aged 18 to 55 years

          -  Body weight ranging from 50 (females) and 60 (males) to110 kg (inclusive)

          -  Must have coagulation test results (including international normalised ratio [INR] and
             activated partial thromboplastin time [aPTT]) within the laboratory reference range at
             Screening.

        Exclusion Criteria:

          -  Presence or history of serious adverse reaction or allergy to any medicinal product

          -  Known contraindication or adverse reaction to warfarin.

          -  Presence of Cytochrome P450 2C9 (CYP2C9) and Vitamin K epoxide reductase complex
             subunit 1 (VKORC1) genetic polymorphisms that are known to increase warfarin
             sensitivity at Screening.

          -  Known contraindications to heparin administration.

          -  Known contraindication to parenteral vitamin K administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Heuer, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuvisan GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical research organization</name>
      <address>
        <city>Neu-Ulm</city>
        <state>Wegenerstra√üe</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

